Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


Effects of Serotonin Transporter Inhibition on the Subjective Response to LSD in Healthy Subjects


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05175430

Organisation Name: University Hospital, Basel, Switzerland

Overal Status: Not yet recruiting

Start Date: March 1, 2022

Last Update: January 3, 2022

Lead Sponsor: University Hospital, Basel, Switzerland

Brief Summary: Lysergic acid diethylamide (LSD) is a classic serotonergic psychedelic acting on the serotonin 5-HT2A receptor. LSD is used recreationally and in psychiatric research. First studies suggest efficacy in psychiatric disorders, such as depression and anxiety. SSRIs like paroxetine are first-line treatments for depression and anxiety disorders. Paroxetine acts as a serotonin transporter (SERT) inhibitor. However, the link between this mechanism and its positive effects on mood remains to be established. Several studies suggest a possible downregulation of postsynaptic serotonin (5-HT) receptors such as the 5-HT2A receptor. The aim of the study is to assess whether SERT inhibition reduces expression of the gene coding for the 5-HT2A receptor and the response to LSD.

Conditions:
  • Healthy


Total execution time in seconds: 0.24377012252808